
Sign up to save your podcasts
Or


The January 2024 replay starts the new year off with four previously posted episodes on dementia. The episode begins with an interview with Dr. Kenneth Langa on the prevalence of dementia and mild cognitive impairment in the US. The episode continues with an interview with Dr. Beau Ances about the burden amyloid has on individuals with Down syndrome compared to autosomal dominant Alzheimer disease. The next interview is with Dr. Erik Musiek on the use of lecanemab in early Alzheimer disease. The fourth and final interview is with Dr. Vijay Ramanan on the eligibility for anti-amyloid treatment.
Related Podcast Links:
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the United States: https://directory.libsyn.com/episode/index/id/25811241
Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25881414
Lecanemab in Early Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25428333
Eligibility for Anti-Amyloid Treatment: https://directory.libsyn.com/episode/index/id/28300052
Related Article Links:
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: https://jamanetwork.com/journals/jamaneurology/article-abstract/2797274?resultClick=1
Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer's Disease: A Cross-Sectional Study: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00408-2/fulltext
Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging: https://www.neurology.org/doi/10.1212/WNL.0000000000207770
Disclosures can be found at Neurology.org
By American Academy of Neurology4.7
284284 ratings
The January 2024 replay starts the new year off with four previously posted episodes on dementia. The episode begins with an interview with Dr. Kenneth Langa on the prevalence of dementia and mild cognitive impairment in the US. The episode continues with an interview with Dr. Beau Ances about the burden amyloid has on individuals with Down syndrome compared to autosomal dominant Alzheimer disease. The next interview is with Dr. Erik Musiek on the use of lecanemab in early Alzheimer disease. The fourth and final interview is with Dr. Vijay Ramanan on the eligibility for anti-amyloid treatment.
Related Podcast Links:
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the United States: https://directory.libsyn.com/episode/index/id/25811241
Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25881414
Lecanemab in Early Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25428333
Eligibility for Anti-Amyloid Treatment: https://directory.libsyn.com/episode/index/id/28300052
Related Article Links:
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: https://jamanetwork.com/journals/jamaneurology/article-abstract/2797274?resultClick=1
Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer's Disease: A Cross-Sectional Study: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00408-2/fulltext
Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging: https://www.neurology.org/doi/10.1212/WNL.0000000000207770
Disclosures can be found at Neurology.org

320 Listeners

497 Listeners

50 Listeners

292 Listeners

3,348 Listeners

13 Listeners

1,145 Listeners

24 Listeners

193 Listeners

513 Listeners

135 Listeners

369 Listeners

190 Listeners

374 Listeners

83 Listeners